GBT News and Press, Global Blood Therapeutics Inc. From 09/08/22

SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11 th Annual Sickle Cell Disease (SCD) Therapeutics Co...

NEW YORK, NY / ACCESSWIRE / September 1, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Global Blood Therapeutics, Inc. ...

Pfizer ( NYSE: PFE ) is said to have been involved in a bidding war with Johnson & Johnson ( NYSE: JNJ ) to acquire Global Blood Therapeutics ( NASDAQ: GBT ) before Pfizer won with its $5.4 billion offer. Johnson & Johnson ( JNJ ) is the unident...

According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical company Global Blood Therapeutics (NASDAQ: GBT) for $5 billion. Pfizer, too, acquired Global Blood Therapeutics  Pfizer wants ...

Pfizer has become extremely cash-rich thanks to its development of COVID vaccine Comirnaty and antiviral Paxlovid. The market knows that these drug sales will likely fall dramatically, which explains PFE's poor share price performance in 2022. Pfizer has been doing M&A deals t...

Stock market expectations have shifted to a relatively more benign Federal Reserve rate outlook, thus driving a sharp rally. The market is approaching a key technical level. Healthcare has relatively outperformed the market and has been consolidating. Biotechs found a bottom a...

On May 18, I wrote the first of three articles stating that healthcare stocks, and specifically biopharmaceuticals, had likely bottomed. XBI was at 68 and IBB 114. Both XBI and IBB have increased since then. I viewed the valuations a few months ago as being compelling in several insta...

Pfizer is a high-quality, high-yielding pharmaceutical company backed up by a robust drug portfolio. We appreciate Pfizer's decision to spinoff its Upjohn generics business, which was completed back in 2020, as the deal raised billions for Pfizer and ample synergies are expected going...

NEW YORK, NY / ACCESSWIRE / August 11, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Global Blood Therapeutics, Inc. (N...

NEW YORK, NY / ACCESSWIRE / August 10, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Global Blood Therapeutics, Inc. (N...